Multiple outlets report a sharp rise in NHS spending and prescribing for Mounjaro (tirzepatide), a weight-loss medicine. The reported cost increase is described as four-fold over the course of one year, reaching more than £500 million. Alongside higher expenditure, prescriptions for the drug also increase substantially. One set of figures states that Mounjaro prescriptions grow from 1.1 million in 2024/25 to 3.1 million in 2025/26. The same reporting indicates that, based on the latest available spending totals, the drug’s bill is higher than that for any other medication. The reports refer to Mounjaro by its active ingredient name, tirzepatide, and use a nickname in describing its popularity. Taken together, the coverage focuses on the scale of growth in both demand and spending within the NHS over the cited period. The information is presented as prescription and spending data for the NHS financial years 2024/25 and 2025/26.